文献速递造血干细胞移植与细胞治疗

嵌合抗原受体T细胞治疗后巨细胞病毒再激活的发生率与结局

Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.
PubMed 文献 · Blood Adv · 2024-01-01

该研究纳入2018年2月至2023年2月期间接受CAR-T细胞治疗的95例成人CMV血清学阳性患者,报告CMV再激活(任何病毒血症)发生率为33%(31例),临床显著CMV感染(cs-CMV)为11%(10例),中位再激活时间为19天。使用糖皮质激素、阿那白滞素或≥2种免疫抑制剂与CMV再激活和cs-CMV均相关,CMV再激活者1年死亡率显著更高(57% vs 23%;P=.001)。

要点

  • CAR-T治疗后CMV再激活(任何病毒血症)发生率为33%,cs-CMV为11%。
  • 3-4级细胞因子释放综合征、使用糖皮质激素、阿那白滞素或≥2种免疫抑制剂者CMV再激活率更高。
  • CMV再激活者1年死亡率显著高于无再激活者(57% vs 23%;P=.001)。

核心结论

  • 为管理CAR-T细胞毒性而使用的免疫抑制,尤其是糖皮质激素,是CMV再激活的主要危险因素。
  • CMV再激活者的1年死亡率显著高于无再激活者(57% vs 23%;P=.001)。

研究设计与样本

  • 研究报告了2018年2月至2023年2月期间接受CAR-T细胞治疗的95例成人CMV血清学阳性患者的CMV再激活发生率与结局。
  • CMV结局定义为CMV再激活(任何病毒血症)和临床显著CMV感染(cs-CMV)。

主要发现

  • 31例患者(33%)有CMV再激活(任何病毒血症)证据,10例患者(11%)发生cs-CMV。
  • 从CAR-T细胞输注至CMV再激活的中位时间为19天(四分位距[IQR],9-31)。
  • 3-4级细胞因子释放综合征患者的CMV(任何病毒血症)累积发生率显著更高(67% vs 28%;P=.01)。
  • 接受糖皮质激素者CMV累积发生率显著更高(39% vs 21%;P=.03),接受阿那白滞素者显著更高(56% vs 28%;P=.02),接受≥2种免疫抑制剂者显著更高(41% vs 21%;P=.02)。
  • 接受糖皮质激素(18% vs 0%;P=.004)、托珠单抗(14% vs 0%;P=.04)、阿那白滞素(33% vs 7%;P=.008)和≥2种免疫抑制剂(20% vs 0%;P=.001)均与cs-CMV相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lin RY, Anderson AD, Natori Y, et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024. PMID: 38838226. doi:10.1182/bloodadvances.2024012922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。